Merck & Co., Inc. Licenses SNALP Technology From Protiva Biotherapeutics

VANCOUVER, BRITISH COLUMBIA--(Marketwire - October 16, 2007) - Protiva Biotherapeutics Inc. today reported that it has granted Merck & Co., Inc. a non-exclusive license to Protiva's SNALP (Stable Nucleic Acid-Lipid Particles) technology for ongoing research and development of therapeutics in the emerging field of RNA interference (RNAi).

Back to news